Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of vitamin B1, cordycepic acid and riboflavin and composition thereof in uric acid-lowering drugs

A technology for lowering uric acid and vitamins, applied in the directions of drug combinations, active ingredients of heterocyclic compounds, active ingredients of hydroxy compounds, etc., can solve the problems of high risk, easy to cause gastrointestinal and cardiovascular diseases, etc.

Inactive Publication Date: 2017-05-24
GUANGDONG INST OF MICROORGANISM +1
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the drugs used to reduce the concentration of uric acid in the human body mainly include: inhibiting uric acid synthesis, promoting uricosuric excretion and uricase-like drugs, including allopurinol, febuxostat, benzbromarone, probenecid, Lesinurad, uricase , Rasburicase, PEG-modified uricase, etc. These drugs have strong side effects on liver and kidney metabolic organs or cause immune reactions in the body to produce antibodies, and are also likely to cause gastrointestinal and cardiovascular diseases
This makes patients with liver and kidney disease, gout patients with high blood pressure, congestive heart failure, gastritis / ulcer, or renal insufficiency generally more risky to use the above drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of vitamin B1, cordycepic acid and riboflavin and composition thereof in uric acid-lowering drugs
  • Application of vitamin B1, cordycepic acid and riboflavin and composition thereof in uric acid-lowering drugs
  • Application of vitamin B1, cordycepic acid and riboflavin and composition thereof in uric acid-lowering drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Vitamin B 1 , cordycepic acid, riboflavin and compositions thereof at the same dose (20mg / kg / d) on hyperuric acid mice:

[0035] 70 male SPF Kunming mice (20±2g, purchased from Southern Medical University) were randomly divided into 7 groups: normal control group, model control group, positive control group, vitamin B 1 group, cordycepic acid group, riboflavin group, composition group (vitamin B 1 , cordycepic acid, and riboflavin in a mass ratio of 1:1:1). In addition to intraperitoneal injection and intragastric administration of normal saline in the normal control group, the other groups were intraperitoneally injected oxonate potassium salt at a dose of 100 mg / kg / d, and at the same time administered intragastric hypoxanthine at a dose of 600 mg / kg / d to establish a small hyperuricemia mouse model. One hour before modeling, fasting without water, 1 hour after modeling, the positive control group was given 5 mg / kg / d dose of allopurinol (AL), vitamin B 1 The group w...

Embodiment 2

[0040] Vitamin B 1 , cordycepic acid, riboflavin and their compositions in different doses of hyperuric acid mice, mechanism of action and toxicology experiments:

[0041] Reagent sources: Potassium oxonate and hypoxanthine were purchased from Aldrich Reagent Company, allopurinol was provided by Tokyo Chemical Co., Ltd., benzbromarone riboflavin, vitamin B1 and cordycepic acid were purchased from Aladdin Reagent Co., Ltd. Serum uric acid level detection kit was purchased from Nanjing Jiancheng Bioengineering Institute. XOD detection kit and URAT1 protein detection kit were purchased from R&D System.

[0042] Experimental animals: All animal experiment plans were approved by the Ethics Committee of Guangdong Institute of Microbiology (GT-IACUC201608151). Male SPF grade Kunming mice (20±2g) used in this study were purchased from the Guangdong Medical Experimental Animal Center. One week before the experiment, all animals were raised in a barrier environment and allowed to eat ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of riboflavin, vitamin B1 and cordycepic acid and a composition thereof in uric acid-lowering drugs. In-vivo experiment results indicate that all riboflavin, vitamin B1 and cordycepic acid can reduce the content of uric acid in serum, wherein the uric acid-lowering effect of riboflavin is most significant, and the three compounds have a synergistic effect and have no toxicity on liver, kidney and spleen. The experiment results indicate that the uric acid-lowering activity is probably due to the inhibition of URAT1 proteins.

Description

[0001] 【Technical field】 [0002] The invention belongs to the field of medicine and health care, in particular to vitamin B 1 , cordycepic acid, riboflavin and their composition in the application of uric acid-lowering drugs. [0003] 【Background technique】 [0004] Gout seriously plagues human life. Epidemiological studies in New Zealand, the United States and China have shown that gout is becoming more and more common, with an incidence rate of about 2% and increasing. Among them, the incidence rate is highest in people aged 65 and over, and the incidence rate of men is twice as high as that of women. Gout is the result of the development of hyperuricemia. It is because the concentration of uric acid in the body is higher than the dissolving capacity of the blood (>360μmol / L), resulting in the deposition of sodium urate crystals in soft tissues and joints. These deposited crystals cause repeated inflammation of soft tissues, joints and bone tissues severe pain, seriousl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/525A61K31/51A61K31/047A61P19/06
CPCA61K31/525A61K31/047A61K31/51A61K2300/00
Inventor 雍天乔谢意珍焦春伟
Owner GUANGDONG INST OF MICROORGANISM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com